Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells

The invasin D protein fromYersinia pseudotuberculosisselectively binds the Fab region of host antibodies and affects colonization of the intestine

(2018) Pooja Sadana et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response

(2016) Andrew R. Conery et al.   CANCER RESEARCH

Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases

(2016) Jennifer M. Sahni et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

(2016) Shaokun Shu et al.   NATURE

Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse

(2016) Marco Demaria et al.   Cancer Discovery

Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy

(2015) Elias E. Stratikopoulos et al.   CANCER CELL

Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice

(2015) Jianhui Chang et al.   NATURE MEDICINE

BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice

(2015) Erica Korb et al.   NATURE NEUROSCIENCE

Disrupting the Interaction of BRD4 with Diacetylated Twist Suppresses Tumorigenesis in Basal-like Breast Cancer

(2014) Jian Shi et al.   CANCER CELL

Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers

(2013) Jakob Lovén et al.   CELL

BET Protein Function Is Required for Inflammation: Brd2 Genetic Disruption and BET Inhibitor JQ1 Impair Mouse Macrophage Inflammatory Responses

(2013) A. C. Belkina et al.   JOURNAL OF IMMUNOLOGY

Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities

(2012) D. W. Craig et al.   MOLECULAR CANCER THERAPEUTICS

Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44+CD24lo cancer stem cell phenotype

(2011) James M. Reuben et al.   EUROPEAN JOURNAL OF CANCER

Mitotic catastrophe: a mechanism for avoiding genomic instability

(2011) Ilio Vitale et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Phosphorylation of Mcl-1 by CDK1–cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest

(2010) Margaret E Harley et al.   EMBO JOURNAL

Survivin and escaping in therapy-induced cellular senescence

(2010) Qin Wang et al.   INTERNATIONAL JOURNAL OF CANCER

The CD44+/CD24− phenotype relates to ‘triple-negative’ state and unfavorable prognosis in breast cancer patients

(2010) Alexandra Giatromanolaki et al.   MEDICAL ONCOLOGY

Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists

(2010) Sunil Badve et al.   MODERN PATHOLOGY

Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design

(2009) Farrah Kassam et al.   Clinical Breast Cancer

Cyclin-Dependent Kinase 1-Mediated Bcl-xL/Bcl-2 Phosphorylation Acts as a Functional Link Coupling Mitotic Arrest and Apoptosis

(2009) D. T. Terrano et al.   MOLECULAR AND CELLULAR BIOLOGY

What is triple-negative breast cancer?

(2008) William J. Irvin et al.   EUROPEAN JOURNAL OF CANCER

The consequences of tetraploidy and aneuploidy

(2008) Z. Storchova et al.   JOURNAL OF CELL SCIENCE

Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor

(2008) Jean-Philippe Coppé et al.   PLOS BIOLOGY